Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study
The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.
Conditions studied
Postpartum Preeclampsia
About this study
The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.
Interventions
- Other: Early detection and management of postpartum preeclampsia bundle — Remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.
Primary outcomes
- Study feasibility (1 year)
Eligibility information
Study locations
- Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
- Dhulikhel Hospital, Dhulikhel, Nepal
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.